Voriconazole is commonly used in antifungal therapy, and there is generally no fixed duration of discontinuation; the length of use depends on the site of infection, underlying disease, and immunosuppression, but discontinuation of the drug is required when a serious adverse event occurs.
Invasive aspergillosis taking voriconazole treatment for at least 7 days; for allogeneic stem cell transplant recipients, if tolerated for at least 75 days; (central nervous system disease) downgraded treatment (after amphotericin B liposome initiation therapy), at least 1 year of drug use, and cerebrospinal fluid examination is not abnormal, so it is necessary to decide to discontinue the medication according to their own disease, underlying diseases, immunosuppression, and under medical guidance Duration.
If treatment with voriconazole is continued for more than 28 days, visual functions such as vision, visual range, and color perception will need to be tested. Physicians should closely monitor for potential adverse effects and make timely adjustments to the drug regimen based on the patient’s specific condition. Voriconazole is a prescription medication and needs to be taken under a doctor’s supervision.
Common adverse reactions to voriconazole include hepatic function abnormalities, visual disturbances, neurologic/psychiatric disorders, and skin and subcutaneous tissue abnormalities.
With reference to the common adverse events evaluation criteria 4.0 for the grading of adverse events, hepatic function abnormalities, neurological/psychiatric disorders and visual disturbances of grade 3 adverse events as an indication for discontinuation of the drug, and recommended that grade 2 adverse events as an indication for dosage reduction, if voriconazole dosage reduction after the patient is still unable to tolerate the adverse events, the discontinuation of the drug should be considered for treatment. Voriconazole can cause fetal damage in pregnant women and should be avoided if possible.